Ascendiant Capital initiated coverage on Daxor with a new price target
$DXR
Medical/Dental Instruments
Health Care
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
N-2/A - DAXOR CORP (0000027367) (Filer)
N-CSR/A - DAXOR CORP (0000027367) (Filer)
N-PX - DAXOR CORP (0000027367) (Filer)
Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City. Mr. Feldschuh will be available for one-on-one meetings with institutional investors and will also meet with senior Maxim analysts throughout the event. The conference features high-profile
OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across the country. "We are thrilled to debut our eagerly awaited next generation BVA diagnostic system at this pivotal gathering," said Michael Feldschuh, Daxor's CEO and President. "This launch
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company's successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market. The initial response from clinicians confirmed robust market demand for the new system, driven b
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
3 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh
Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio